Xcout IntelEikon Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Eikon Therapeutics, Inc. among biotechnology companies — ranked by similarity to what Eikon Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Eikon Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Eikon Therapeutics, Inc. at a glance
Eikon Therapeutics, Inc. is a biotechnology company headquartered in Millbrae, United States. It is publicly listed (EIKN) with a market capitalisation of $404.4M. Xcout tracks 29 named people at Eikon Therapeutics, Inc., including Roger Perlmutter (Chairman, President & CEO). Xcout recorded 94 job postings from Eikon Therapeutics, Inc. in the last 90 days, naming tools such as SAP, SuccessFactors.
Eikon Therapeutics, Inc. leadership
- Roger PerlmutterChairman, President & CEO
- Roger M PerlmutterChief Executive Officer
- Michael A KlobucharChief Operating Officer
- Mike KlobucharChief Operating Officer
- Alfred BowieChief Financial Officer
- Alfred Lloyd Bowie Jr.Treasurer & CFO
23 more named people on record for Eikon Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Eikon Therapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $350.7M | 8 named | |
| Series D | $148M | 8 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Eikon Therapeutics, Inc.
Xcout recorded 94 job postings from Eikon Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Eikon Therapeutics, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Eikon Therapeutics, Inc.'s hiring signals →
Recent Eikon Therapeutics, Inc. news
- IPOIPO registration (S-1)
- IPOIPO registration (S-1)
- IPOEikon plans IPO to bankroll clutch of clinical cancer drugs
4 corporate events on record, with sources — see the full timeline →
Top 12 Eikon Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Eikon Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Parabilis Medicines is a biopharmaceutical company that develops ultra-tunable peptide therapeutics utilizing its proprietary Helicon platform. The company focuses on creating novel medicines to target historically undruggable conditions, primarily addressing cancer and other serious diseases with critical medical needs.
Biotech
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Similar biotechnology company
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.
Similar biotechnology company
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Biotech
Aelin Therapeutics is a biopharmaceutical company based in Leuven, Belgium, that develops peptide-based novel drug modalities and biotherapeutic technology platforms designed to induce functional knockdown of target proteins through protein aggregation.
Similar biotechnology company
NERx Biosciences, Inc. is a small business enterprise headquartered in Indianapolis, Indiana, dedicated to the discovery and development of targeted therapeutics for cancer.
Biotech
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Similar biotechnology company
Matchpoint Therapeutics Inc. discovers and develops precision small molecule medicines utilizing covalent chemistry and chemoproteomics screening to treat immune diseases. The company leverages proprietary screening technologies and machine learning algorithms to expand the druggable proteome and design covalent drug candidates for patients with serious inflammatory and immune conditions.
Similar biotechnology company
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
Biotech
Atavistik Bio is a U.S. biotechnology company developing small-molecule medicines by targeting allosteric sites and metabolite-regulated biology, using its chemoproteomics and drug-discovery platform. Its programs are aimed at treating cancer and other serious diseases.
Biotech
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Similar biotechnology company
Noetik Inc. is an AI-native biotechnology company headquartered in South San Francisco, California, leveraging advanced machine learning methods for biological discovery.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Eikon Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Eikon Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →